All In MedTech

FDA Clearance Tracker · P170043

iStent inject Trabecular Micro-Bypass System (Model G2-M-IS)

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Jun 21, 2018 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Jun 21, 2018

Approved

Time to decision

182 days

Received Dec 21, 2017. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P170043
Device name
iStent inject Trabecular Micro-Bypass System (Model G2-M-IS)
Applicant location
San Clemente, CA
Received
Dec 21, 2017
Decided
Jun 21, 2018
Decision
Approved
Supplements
19 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III
Specialty
Ophthalmology

Every decision under product code OGO

FDA's approval statement

As written in FDA's record.

Approval for the iStent inject® Trabecular Micro-Bypass System (Model G2-M-IS). This device is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate primary open-angle glaucoma.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code OGO. The earliest in FDA's data is P000026, decided Jul 12, 2001.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Glaukos Corporation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.